News

Video

Dr Peters on Understanding Mechanisms of Resistance to Immunotherapy in NSCLC

Author(s):

Solange Peters, MD, PhD
Conference|International Lung Cancer Congress

Solange Peters, MD, PhD, discusses current understandings of mechanisms of resistance to immunotherapy in non–small cell lung cancer.

Solange Peters, MD, PhD, full professor, chair, Medical Oncology, Thoracic Malignancies Programme, Department of Oncology, University Hospital of Lausanne, discusses current understandings of mechanisms of resistance to immunotherapy in non–small cell lung cancer.

Related Videos
Sattva S. Neelapu, MD
David L. Porter, MD
Suneel Kamath, MD
Craig E. Devoe, MD, MS
Yoshie Umemura, MD, division chief, Neuro-Oncology, William R. and Joan R. Shapiro Chair for Neuro-Oncology Research, associate professor, neurology, Barrow Neurological Institute, chief medical officer, Ivy Brain Tumor Center
Adam M. Burgoyne, MD, PhD, associate clinical professor, medicine, the University of California San Diego
Julia Foldi, MD, PhD
Joaquim Bellmunt, MD, PhD
Brandon Huffman, MD
Sattva S. Neelapu, MD
Related Content
Allison Graeter, MD
June 12th 2024

Talquetamab Produces Responses in R/R Myeloma After Prior T-Cell–Directed Therapies

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Lakshmi Nayak, MD, director, Center for CNS Lymphoma, Dana-Farber Cancer Institute; associate professor, neurology, Harvard Medical School
June 11th 2024

Axi-Cel Shows Safety, Clinical Activity in R/R Primary and Secondary CNS Lymphomas

Hari B. Keshava, MD
October 23rd 2023

Keshava Emphasizes the Importance of Lung Nodule Programs for Early Lung Cancer Detection

Michael J. Morris, MD
June 10th 2024

JNJ-6420 Elicits Responses in mCRPC, But Safety Concerns Arise

Fabrice Barlesi, MD, PhD
June 10th 2024

Adjuvant Alectinib Approved in Europe for ALK+ Early-Stage NSCLC